Seattle, WA, United States of America

Douglas Pat Cerretti



 

Average Co-Inventor Count = 2.1

ph-index = 14

Forward Citations = 532(Granted Patents)


Location History:

  • Seattle, WA (US) (1989 - 2012)
  • Shoreline, WA (US) (2010 - 2018)

Company Filing History:


Years Active: 1989-2018

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
C-FMS Antigen Binding Proteins
C-FMS Antibodies
TNF-Alpha Converting Enzyme
Metalloprotease-Disintegrin ADAM23
Integrin Antagonists
Cytokines
Recombinant Cytokines
Polynucleotides
Tek Antagonists
Human Interleukin
Macrophage Colony Stimulating Factor
Bovine Interleukin
45 patents (USPTO):Explore Patents

Title: Overview of Douglas Pat Cerretti’s Contributions to Biotech Innovations

Introduction: Douglas Pat Cerretti is a prominent inventor based in Seattle, WA, known for his significant contributions to the field of biotechnology. With a remarkable portfolio of 45 patents, Cerretti's work primarily focuses on antigen binding proteins and their applications in cancer therapy.

Latest Patents: Among his latest innovations are the "Human C-FMS Antigen Binding Proteins" and "Human C-FMS Antibodies." These patents detail proteins that bind to the human c-fms protein, along with nucleic acids encoding these proteins, vectors, and cells capable of encoding the same. The technologies developed can inhibit the binding of c-fms to CSF-1, reducing the migration of monocytes into tumors, and ultimately decreasing the accumulation of tumor-associated macrophages. These advancements have the potential to significantly impact cancer treatment methodologies.

Career Highlights: Throughout his career, Douglas Pat Cerretti has worked with prestigious companies such as Immunex Corporation and Amgen Inc. His tenure at these companies has allowed him to refine his expertise and contribute to groundbreaking research within the biotech industry.

Collaborations: In his professional journey, Cerretti has collaborated with notable colleagues, including Carl J March and Roy A Black. Their combined efforts have spurred innovation and have strengthened the foundations of their respective research areas.

Conclusion: Douglas Pat Cerretti's extensive patent portfolio and collaborative endeavors reflect his commitment to advancing biotechnological innovations. His work with antigen binding proteins not only showcases his ingenuity as an inventor but also underscores the potential for significant impacts in the field of cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…